Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and Drug Administration (FDA) ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

During the conference, Can-Fite's management team will engage in one-on-one meetings with investors and potential partners to discuss the company’s business strategy, recent clinical milestones, and ...

A patent has been granted in the US covering the use of Neurizon’s lead drug candidate NUZ-001 in neurodegenerative diseases ...

DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), is developing ...

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

Despite some market exclusivity concerns, GERN still has many years of sales ahead, unencumbered by generic competition.

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...